A Cochrane review included 5 trials involving a total of 117 participants. One study reported on the 'masking' effects of molindone and haloperidol on tardive dyskinesia (TD), which favoured haloperidol (RR 3.44 CI 1.1 to 5.8, n=18). 2 studies found no reduction in TD associated with neuroleptic reduction (RR 0.38 CI 0.1 to 1.0, n=17). One study found no differences in oral dyskinesia (RR 2.45 CI 0.3 to 19.7, n=20) when neuroleptics were compared as a specific treatment for TD. Dyskinesia was found to be not significantly different (RR 0.62 CI 0.3 to 1.26, n=32) between quetiapine and haloperidol when used as specific treatments for TD.
Comment: The quality of evidence is downgraded by study quality (unclear allocation concealment) and imprecise results (few patients and wide confidence intervals, and limited study size for each comparison).